Although PTPRR is only mutated in 1% of PCa tumours [11], our data demonstrates that it is a key component of the clinically important RAS/ERK1/2 signalling pathway, and that its expression level can have a clear affect on the activity of this pathway. This evidence concerns the gene PTPRR and neoplasm.